#United States #San Diego #Aspen Neuroscience #ANPD001 #Myatos

Aspen Neuroscience Accelerates Production of Personalized Cell Therapies for Parkinson's Disease

Aspen Neuroscience, Inc. is making significant strides in the automated manufacturing of ANPD001, its investigational cell therapy targeting individuals with Parkinson's disease (PD). The company has announced a comprehensive capacity expansion at its San Diego Good Manufacturing Practice (GMP) facility, which aims to enhance efficiency and increase the production of this promising treatment.

The GMP facility, specifically designed for the production and testing of ANPD001, spans 22,000 square feet, and an additional 8,000 square feet is being added to support future automation processes. This expansion is crucial for advancing the company's ongoing ASPIRO Phase 1/2a clinical trial, where ANPD001 is currently being evaluated.

A notable aspect of this plan includes a collaboration with Mytos, a prominent player in automated cell manufacturing. This partnership is focused on the automation of dopaminergic neuronal precursor cells (DANPCs) integral to ANPD001. Essentially, these cells are developed from patient-specific induced pluripotent stem cells (iPSCs) that are derived from the patient's skin cells. By using this autologous method, Aspen aims to replenish lost dopamine-producing neurons in the brains of PD patients without necessitating the use of immunosuppressive drugs.

Kim Raineri, Chief Technology Officer at Aspen Neuroscience, emphasized the importance of the Mytos partnership in streamlining production, stating: "This collaboration addresses an important step for automating the manufacturing process for the differentiation of DANPCs from induced pluripotent stem cells. The Mytos platform, alongside our proprietary bioinformatics and enabling technologies, will facilitate further automation of ANPD001 production, allowing us to treat more patients effectively."

The quality assurance of ANPD001 is rigorous; each manufacturing stage involves the application of Aspen's proprietary genomic platforms, coupled with various in vitro and in vivo assays, along with machine learning techniques for genetic testing. These protocols are designed to ensure that the highest standards of product quality are consistently met.

In alignment with its mission to offer personalized cell therapies to patients facing significant medical challenges, Aspen Neuroscience continues to innovate in the field of regenerative medicine. This includes the ongoing development of iPSC-derived therapies, as well as significant investments in their manufacturing capabilities. Recently, the company disclosed further plans for scaling manufacturing operations, which encompasses its facility expansion and a collaboration with Cell X Technologies aimed at automating the iPSC stage of its autologous cell therapy production process.

About Aspen Neuroscience

Located in San Diego, Aspen Neuroscience, Inc. is a private company dedicated to clinical development in the field of autologous regenerative medicine. By harnessing a patient-derived platform, the company creates personalized cell therapies that address diseases with high unmet medical needs, beginning with neuron replacement for Parkinson's disease. For additional information and updates, visit Aspen Neuroscience.

About Mytos

Mytos is known for its leadership in automated cell manufacturing, providing a platform that enables precision and efficiency in cultivating human cells. The company has assembled a top-tier team of engineers and scientists dedicated to developing automated solutions that can expedite the availability of life-saving therapies. Based in London, UK, Mytos can be explored further at Mytos Bio.